Daiichi Sankyo : "R&D Day 2021"

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Sunao Manabe, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange)

Please address inquiries to Junichi Onuma, Vice President, Corporate Communications Department Telephone: [phone] https://www.daiichisankyo.com

Daiichi Sankyo's "R&D Day 2021"

Tokyo, Japan (December 14, 2021) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) will hold its "R&D Day 2021" at 7:30am JST on Wednesday, December 15, 2021 for institutional investors, security analysts and media.

In addition to the Zoom webinar, on-demand recorded video will be available at a later date. URL: https://www.daiichisankyo.com/investors/library/materials/2021.html

Attachment: presentation material

R&D Day 2021

DAIICHI SANKYO CO., LTD.

Dec 14/15, 2021

Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere. This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.

2

Speakers

Sunao Manabe	Ken Takeshita	Wataru Takasaki	Tohru Takahashi	Gilles Gallant
Head of Research
President and CEO	Head of Global R&D	Head of Japan R&D	Head of Global
Function
			Oncology Development

3

Agenda

1. Introduction
2. R&D strategy
3. Q&A session

4